Macmillan Cancer Support, the leading UK cancer charity, has invested in Neutrocheck® – a portable device and accompanying app in development from 52 North Health – with the aim to help people with cancer test their risk of life-threatening neutropenic sepsis at home rather than having to be tested in an emergency at hospital. ThisContinue reading “Macmillan launches new £3.5million Innovation Impact Investment Portfolio by investing in pioneering at-home neutropenic sepsis test, Neutrocheck®.”